Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internationally. More Details
No risks detected for ATRI from our risk checks.
Flawless balance sheet second-rate dividend payer.
Share Price & News
How has Atrion's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ATRI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ATRI's weekly volatility (5%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: ATRI underperformed the US Medical Equipment industry which returned 27.3% over the past year.
Return vs Market: ATRI underperformed the US Market which returned 34.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Atrion's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShould You Be Impressed By Atrion's (NASDAQ:ATRI) Returns on Capital?
4 weeks ago | Simply Wall StAre Robust Financials Driving The Recent Rally In Atrion Corporation's (NASDAQ:ATRI) Stock?
1 month ago | Simply Wall StAtrion (NASDAQ:ATRI) Shareholders Have Enjoyed A 89% Share Price Gain
Is Atrion undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ATRI ($630.63) is trading above our estimate of fair value ($367.13)
Significantly Below Fair Value: ATRI is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ATRI is good value based on its PE Ratio (35.4x) compared to the US Medical Equipment industry average (55.5x).
PE vs Market: ATRI is poor value based on its PE Ratio (35.4x) compared to the US market (21.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATRI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATRI is good value based on its PB Ratio (4.8x) compared to the US Medical Equipment industry average (5.1x).
How is Atrion forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Atrion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Atrion's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Healthcare industry.
How has Atrion performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATRI has high quality earnings.
Growing Profit Margin: ATRI's current net profit margins (21.9%) are lower than last year (23.4%).
Past Earnings Growth Analysis
Earnings Trend: ATRI's earnings have grown by 5.3% per year over the past 5 years.
Accelerating Growth: ATRI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ATRI had negative earnings growth (-10%) over the past year, making it difficult to compare to the Medical Equipment industry average (10%).
Return on Equity
High ROE: ATRI's Return on Equity (13.8%) is considered low.
How is Atrion's financial position?
Financial Position Analysis
Short Term Liabilities: ATRI's short term assets ($113.2M) exceed its short term liabilities ($12.7M).
Long Term Liabilities: ATRI's short term assets ($113.2M) exceed its long term liabilities ($12.2M).
Debt to Equity History and Analysis
Debt Level: ATRI is debt free.
Reducing Debt: ATRI has not had any debt for past 5 years.
Debt Coverage: ATRI has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ATRI has no debt, therefore coverage of interest payments is not a concern.
What is Atrion current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ATRI's dividend (1.11%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.34%).
High Dividend: ATRI's dividend (1.11%) is low compared to the top 25% of dividend payers in the US market (3.75%).
Stability and Growth of Payments
Stable Dividend: ATRI's dividends per share have been stable in the past 10 years.
Growing Dividend: ATRI's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (36%), ATRI's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
David Battat (50 yo)
Mr. David A. Battat has been the Chief Executive Officer of ATRION Corp. since May 26, 2011 and has been its President since May 2011. Mr. Battat has been the President of Halkey-Roberts Corporation, a sub...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD1.63M) is about average for companies of similar size in the US market ($USD2.21M).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
|Executive Chairman||23.08yrs||US$636.01k||8.13% |
|Independent Director||33.08yrs||US$132.00k||0.70% |
|Independent Director||36.08yrs||US$140.66k||1.54% |
|Independent Lead Director||no data||US$132.00k||0.12% |
|Independent Director||3.92yrs||US$126.00k||0.027% |
Experienced Board: ATRI's board of directors are seasoned and experienced ( 28.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Atrion Corporation's company bio, employee growth, exchange listings and data sources
- Name: Atrion Corporation
- Ticker: ATRI
- Exchange: NasdaqGS
- Founded: 1944
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$1.153b
- Shares outstanding: 1.83m
- Website: https://www.atrioncorp.com
Number of Employees
- Atrion Corporation
- One Allentown Parkway
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ATRI||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jan 1969|
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internationally. Its fluid delivery produ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/02/24 00:17|
|End of Day Share Price||2021/02/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.